Of the top 20 differentially expressed proteins identified in tumour samples, four (MDH2, FASN, EPCAM, and HSD17B10) are targetable by FDA-approved drugs, whereas two (AMACR and GLYATL1) are potentially targetable (39) and are of potential interest for future research. This evidence concerns the gene FASN and neoplasm.